CY1116346T1 - OXIDATIVE ACTIVE THERAPEUTIC SUBSTANCES FOR THE TREATMENT OF MITCHONDICLE DISEASES AND OTHER DISEASES AND FOR THE REGULATION OF BIOLOGICAL INDICATORS - Google Patents
OXIDATIVE ACTIVE THERAPEUTIC SUBSTANCES FOR THE TREATMENT OF MITCHONDICLE DISEASES AND OTHER DISEASES AND FOR THE REGULATION OF BIOLOGICAL INDICATORSInfo
- Publication number
- CY1116346T1 CY1116346T1 CY20151100256T CY151100256T CY1116346T1 CY 1116346 T1 CY1116346 T1 CY 1116346T1 CY 20151100256 T CY20151100256 T CY 20151100256T CY 151100256 T CY151100256 T CY 151100256T CY 1116346 T1 CY1116346 T1 CY 1116346T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diseases
- treatment
- methods
- disclosed
- mitchondicle
- Prior art date
Links
Abstract
Γνωστοποιούνται μέθοδοι για τη θεραπεία ή την καταστολή μιτοχονδριακών νόσων, όπως αταξία του Friedreich (FRDA), Κληρονομική Οπτική Νευροπάθεια του Leber (LHON), μιτοχονδριακή μυοπάθεια, εγκεφαλοπάθεια, γαλακτική οξέωση, εγκεφαλικό επεισόδιο (MELAS) ή Σύνδρομο Kearns-Sayre (KSS), καθώς και ενώσεις χρήσιμες στις μεθόδους της θεραπείας, όπως κινόνη άλφα-τοκοφερόλης. Γνωστοποιούνται επίσης μέθοδοι και ενώσεις χρήσιμες στη θεραπεία άλλων διαταραχών. Γνωστοποιούνται επίσης βιολογικοί δείκτες ενέργειας χρήσιμοι στην αξιολόγηση της μεταβολικής κατάστασης ενός υποκειμένου και της αποτελεσματικότητας της θεραπείας. Γνωστοποιούνται επίσης μέθοδοι ρύθμισης, κανονικοποίησης ή ενίσχυσης των βιολογικών δεικτών ενέργειας, καθώς και ενώσεις χρήσιμες για αυτές τις μεθόδους.Methods for the treatment or suppression of mitochondrial diseases are disclosed, such as Friedreich's Ataxia (FRDA), Leber Hereditary Optic Neuropathy (LHON), Mitochondrial Myopathy, Encephalopathy, Lactic Acid (KAS) Syndrome as well as compounds useful in methods of treatment, such as quinone alpha-tocopherol. Methods and compounds useful in the treatment of other disorders are also disclosed. Biological energy markers useful in assessing a subject's metabolic status and treatment effectiveness are also disclosed. Methods for regulating, normalizing or enhancing biological energy indices as well as compounds useful for these methods are also disclosed.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68682605A | 2005-06-01 | 2005-06-01 | |
| US70181505A | 2005-07-21 | 2005-07-21 | |
| US77602806A | 2006-02-22 | 2006-02-22 | |
| EP06784530.5A EP1888059B1 (en) | 2005-06-01 | 2006-06-01 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116346T1 true CY1116346T1 (en) | 2017-02-08 |
Family
ID=58457927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100256T CY1116346T1 (en) | 2005-06-01 | 2015-03-13 | OXIDATIVE ACTIVE THERAPEUTIC SUBSTANCES FOR THE TREATMENT OF MITCHONDICLE DISEASES AND OTHER DISEASES AND FOR THE REGULATION OF BIOLOGICAL INDICATORS |
Country Status (1)
| Country | Link |
|---|---|
| CY (1) | CY1116346T1 (en) |
-
2015
- 2015-03-13 CY CY20151100256T patent/CY1116346T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200702622A1 (en) | REDOX-ACTIVE THERAPEUTIC MEANS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | |
| EA201001119A1 (en) | DERIVATIVES (HET) ARYL-P-HINONA FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | |
| EA200800819A1 (en) | VERSIONS OF THE TAIL PART OF REDOX-ACTIVE MEDICINES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY METABOLISM | |
| EA201000756A1 (en) | DERIVATIVES 4- (p-HINONIL) -2-HYDROXYBUTANAMIDE FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | |
| EA200801623A1 (en) | VARIANTS OF REDOX-ACTIVE THERAPEUTIC MEANS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS DIFFERENT IN THE SIDE CHAIN | |
| ES2681477T3 (en) | Pharmaceutical compositions containing lipoic acid in low doses and methods | |
| Babilas et al. | Variable pulsed light is less painful than light‐emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial | |
| Bruzell Roll et al. | Health hazards associated with curing light in the dental clinic | |
| US7858659B2 (en) | Redox therapy for tumors | |
| EP3848059A1 (en) | Apparatus, method and system for selectively affecting and/or killing a virus | |
| Trevisan et al. | Unusual high exposure to ultraviolet‐C radiation | |
| JP2019511343A (en) | Methods, compositions and devices for treating psoriasis with phototherapy | |
| BRPI0615022A8 (en) | ANTIMICROBIAL CATATER | |
| ECSP088984A (en) | DERIVATIVES OF TRIAZOL II | |
| Stangeland et al. | Cold air analgesia as pain reduction during photodynamic therapy of actinic keratoses | |
| Koo et al. | Protection from photodamage by topical application of caffeine after ultraviolet irradiation | |
| Eckermann et al. | Hydrogen is neuroprotective against surgically induced brain injury | |
| Britton et al. | Investigation of the use of the pulsed dye laser in the treatment of Bowen's disease using 5‐aminolaevulinic acid phototherapy | |
| Helm et al. | Skin problems in the long‐distance runner 2500 years after the Battle of Marathon | |
| Han et al. | Evaluation of the skin phototoxicity and photosensitivity of honeybee venom | |
| Cronin et al. | An investigation into the inhibitory effect of ultraviolet radiation on Trichophyton rubrum | |
| Schütz | Blue light and the skin | |
| CY1116346T1 (en) | OXIDATIVE ACTIVE THERAPEUTIC SUBSTANCES FOR THE TREATMENT OF MITCHONDICLE DISEASES AND OTHER DISEASES AND FOR THE REGULATION OF BIOLOGICAL INDICATORS | |
| Davari et al. | Pulsed dye laser treatment with different onset times for new surgical scars: a single-blind randomized controlled trial | |
| O’Grady et al. | Farriery options for acute and chronic laminitis |